HIV Research & Clinical Practice · 2023 · 12 citations · 8 references
PharmacyInfectious DiseasesPharmacotherapyClinical PharmacologyMolecular VirologyVirologyAntiretroviral TherapyAntiviral Drug ResistanceAntiviral PharmacotherapyAntiviral ResistanceAntiviral TherapyHuman Immunodeficiency Virus PharmacotherapyAdherenceAntiviral Safety AssessmentAntiviral Therapy De-escalationAntiviral Therapy DiscontinuationCombination Antiviral TherapyDrug Resistance MutationsResistance-associated MutationsTreatment Discontinuation Rates
BACKGROUND: This real-world study compared the safety and effectiveness of Dolutegravir/lamivudine (D/L) and Bictegravir/Emtricitabine/Tenefovir alafenamide (B/F/T) switch therapy regimens for people living with HIV (PLWH). METHODS: The retrospective study conducted from April 2019 to November 2022, included PLWH with < 50 copies/mL of HIV-RNA prior to recruitment who initiated either D/L or B/F/T switching therapy. The primary objective was to evaluate treatment discontinuation rates; safety and virologic outcomes were also evaluated. RESULTS: = 0.494). Virologic failure (VL > 200 copies/mL in two consecutive measurements) occurred in 1.1% and 0.9% of patients in the D/L and B/F/T groups, respectively. Notably, one patient in D/L group with severe non-adherence and virologic failure developed resistance mutations. CONCLUSIONS: Switching to either B/T/F or D/L treatment for PLWH was effective and well tolerated in this real-world study. Treatment discontinuation rates did not significantly differ between the two regimens.
8
Joel E. Gallant, Adriano Lazzarin, Anthony Mills et al. · The Lancet · 2017 · 380 citations
Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng et al. · Clinical Infectious Diseases · 2022 · 170 citations · Full text
Paul E. Sax, Jürgen K. Rockstroh, Anne F. Luetkemeyer et al. · Clinical Infectious Diseases · 2020 · 112 citations · Full text